 |
|
|
|
Bristol-Myers Squibb currently has 46 product lines which generate more than £25 million each in annual global sales.
Our best-selling medicine is the Cardiovascular drug Plavix® (clopidogrel), developed and promoted in conjunction with
sanofi-aventis, which has already been prescribed to 20 million people worldwide with health problems resulting from vascular disease.
Since 2004, Bristol-Myers Squibb has launched three major new products in the UK: Abilify® (aripiprazole), which was co-developed with Otsuka Pharmaceutical Co. Ltd., Reyataz® (atazanavir), and Perfalgan® (intravenous paracetamol). We hope that a further five will be approved over the next three years. We are working towards approval for several more products over the next few years. We also have a very promising pipeline behind that, specifically within the anti-cancer, Cardiovascular, diabetes, Anti-infective and solid organ transplant rejection therapy areas.
|
|
|
